Search INCY
INCYTE CORP
Nasdaq · CIK 879169
Last close115.3
Daily change-1.84 (-1.57%)
10 Years gain+20.68%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
INCY · STANDARD
SIC 8731 · Services-Commercial Physical & Biological Research · Fiscal year end 1231
Fundamental
81.0Momentum
100.0Acceleration
100.0Confidence
91.0Annual Revenue17
Quarterly Revenue69
Annual CFO11
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth18.3 / 25
Quality15.0 / 25
Capital Efficiency19.3 / 20
Balance Sheet15.0 / 15
Shareholder Economics9.4 / 10
Forward Indicators0.0 / 5
Signals
Operating leverageOperating margin improved by 30.8019 percentage points.
ROIC expansionROIC improved by 66.8631 percentage points.
Net debt reductionNet debt declined versus the comparison period.
Warnings
Inventory anomaly · MEDIUMInventory growth is materially above revenue growth.
Key Metrics
Revenue Growth TTM23.25%OK
Revenue CAGR 3Y14.84%OK
Gross Margin92.76%OK
Operating Margin30.16%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC66.3%OK
Incremental Operating Margin 3Y43.33%OK
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y5.61%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $5.14B | $4.77B | $1.51B | $1.41B | n/a | 92.76% | 29.46% | n/a | 61.16% | 200.7M |
| 2025 FY Dec 31, 2024 | $4.24B | $3.93B | $61.37M | $335.34M | n/a | 92.64% | 1.45% | n/a | 2.42% | 210.53M |
| 2025 FY Dec 31, 2023 | $3.70B | $3.44B | $620.53M | $496.49M | n/a | 93.1% | 16.79% | n/a | 33.36% | 225.93M |
| 2024 FY Dec 31, 2022 | $3.39B | $3.19B | $579.44M | $969.94M | n/a | 93.9% | 17.07% | n/a | 29.51% | 223.96M |
| 2023 FY Dec 31, 2021 | $2.99B | $2.84B | $585.78M | $749.49M | n/a | 94.94% | 19.62% | n/a | 34.12% | 222.07M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $4.91B | sum latest 4 fiscal quarters Revenue | OK | 0000879169-26-000026, 0000879169-25-000103 |
| Revenue Growth TTM | 23.25% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0000879169-26-000026, 0000879169-25-000103 |
| Revenue CAGR 3Y | 14.84% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0000879169-26-000010 |
| Revenue CAGR 5Y | 14.03% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0000879169-26-000010 |
| Gross Profit CAGR 3Y | 14.37% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0000879169-26-000010 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0000879169-26-000026, 0000879169-25-000103 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 92.76% | Gross Profit / Revenue | OK | 0000879169-26-000026, 0000879169-25-000103 |
| Operating Margin | 30.16% | Operating Income / Revenue | OK | 0000879169-26-000026, 0000879169-25-000103 |
| ROIC | 66.3% | NOPAT / Average Invested Capital | OK | 0000879169-26-000026, 0000879169-25-000103 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0000879169-26-000026 |
| Current Ratio | 3.68x | Current Assets / Current Liabilities | OK | derived |
| Revenue per Diluted Share | $23.73 | Revenue / Diluted Shares | OK | 0000879169-26-000026, 0000879169-25-000103 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |